1422-Mechanisms of First-Line Drug Resistance in HCC

This review paper examine how epigenetic regulation—specifically non-coding RNA, DNA methylation, and histone modification—drives resistance to sorafenib and lenvatinib in liver cancer. Research highlights that hepatocellular carcinoma cells survive targeted therapy by rewiring metabolic pathways, expanding cancer stem cell populations, and evading programmed cell death. The text details how abnormal transport processes, such as exosome signaling and drug efflux, further reduce the efficacy of these first-line treatments. By identifying these specific molecular mechanisms, the authors suggest that combining epigenetic therapy with traditional drugs could reverse resistance. Ultimately, the sources advocate for personalized medicine to improve clinical outcomes for patients with advanced liver cancer.References:Qi D, Qin Y, Zhu H, et al. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms[J]. Cell Death & Disease, 2025.前往小宇宙评论区与主播互动